Terns Pharmaceuticals, Inc. (TERN)
- Previous Close
4.5600 - Open
4.5700 - Bid 4.7900 x 200
- Ask 4.8400 x 200
- Day's Range
4.4772 - 4.8500 - 52 Week Range
3.2600 - 13.5100 - Volume
527,929 - Avg. Volume
896,806 - Market Cap (intraday)
311.621M - Beta (5Y Monthly) -0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2700 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.21
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
www.ternspharma.comRecent News: TERN
Performance Overview: TERN
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TERN
Valuation Measures
Market Cap
311.30M
Enterprise Value
48.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.08%
Return on Equity (ttm)
-33.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-90.21M
Diluted EPS (ttm)
-1.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
263.44M
Total Debt/Equity (mrq)
0.24%
Levered Free Cash Flow (ttm)
-36.12M